CJC-1295 With DAC is a growth peptides research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analogue modified with a Drug Affinity Complex — a maleimido-propionyl group that covalently binds to serum albumin via a Michael addition reaction at Cys³ of albumin. This albumin-binding technology dramatically extends the compound's plasma half-life from approximately 7 minutes (for native GHRH(1-29)) to an estimated 6-10 days, enabling infrequent administration in research protocols. The extended half-life distinguishes it sharply from CJC-1295 without DAC (also called Modified GRF 1-29), which has a half-life of approximately 30 minutes.
In rodent research models, CJC-1295 with DAC produces sustained elevation of circulating GH and IGF-1, with a pharmacokinetic profile more analogous to GH baseline elevation than the pulsatile GH release produced by short-acting GHRH analogues or GHRPs. This distinction has significant implications for research design: pulsatile versus continuous GH elevation engage different downstream signaling patterns and tissue responses. CJC-1295 with DAC is widely used in GH axis research where sustained receptor occupancy at GHRHR rather than pulsatile stimulation is the experimental requirement.
PeptidesFromChina.co supplies CJC-1295 with DAC as a lyophilized powder in sealed vials at 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | GHRH analogue with Drug Affinity Complex (albumin-binding) |
|---|---|
| Synonyms | CJC-1295 DAC, DAC:GRF, GRF with DAC |
| Amino Acids | 30 (GHRH(1-29) backbone with DAC modification) |
| Molecular Weight | ~3459 Da |
| CAS Number | 863288-34-0 |
| Receptor Target | GHRHR (growth hormone-releasing hormone receptor) |
| Half-Life (approximate) | 6-10 days (albumin-bound) |
| Research Areas | GH axis pharmacology, sustained GHRH receptor stimulation, IGF-1 regulation, pituitary function |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (use within 2 weeks) |
| Molecular Formula | N/A — DAC-modified 29-aa peptide |
| Sequence | Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (+ Drug Affinity Complex) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| CJC-1295 With DAC | 2 mg | 10 vials | ≥98% | In Stock | $94.00 |
| CJC-1295 With DAC | 5 mg | 10 vials | ≥98% | In Stock | $194.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer's internal quality-control records and are not issued as a separate certificate or document.
CJC-1295 with DAC enables sustained GHRHR activation over days rather than minutes, producing a distinct pharmacodynamic profile compared to short-acting GHRH analogues. Research has examined how prolonged GHRHR occupancy affects GH pulse architecture, IGF-1 accumulation, and pituitary somatotroph behavior. This sustained profile is used as an experimental counterpoint to pulsatile GH secretion models in GH axis biology.
The DAC modification — maleimido-propionyl-lysine enabling covalent albumin binding — is itself a pharmacokinetic research tool. Studies examining DAC-modified compounds have contributed to understanding of albumin-binding half-life extension strategies, reaction kinetics of maleimide-thiol conjugation in vivo, and the pharmacokinetic implications of albumin as a drug carrier. CJC-1295 with DAC is a well-characterized model compound in this field.
Research protocols using CJC-1295 with DAC have examined downstream GH axis effects including IGF-1 elevation, GH-responsive tissue changes in rodent models, and pituitary feedback regulation. Its use in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin) allows researchers to study synergistic GHRHR and GHS-R1a co-stimulation under conditions of prolonged versus acute GHRH receptor engagement.
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes — it stimulates a single GH pulse and is cleared rapidly. CJC-1295 with DAC binds albumin covalently, extending its half-life to 6-10 days and producing sustained GHRHR stimulation. They represent fundamentally different pharmacodynamic tools despite sharing the GHRH sequence backbone.
Yes — combining CJC-1295 with DAC (GHRHR agonist) and a GHRP such as ipamorelin, GHRP-2, or GHRP-6 (GHS-R1a agonists) is a common research design. The two receptor systems are mechanistically synergistic, and co-stimulation produces GH pulse amplification beyond what either compound achieves alone.
CJC-1295 with DAC is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control.
The DAC is a maleimido-propionyl group attached to a lysine residue in the peptide sequence. In plasma, it reacts with cysteine-34 of serum albumin via a Michael addition, forming a stable covalent bond. The albumin-bound complex has the long circulating half-life of albumin (~19 days), significantly extending effective half-life compared to the free peptide.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.